1. Home
  2. BBAR vs IMNM Comparison

BBAR vs IMNM Comparison

Compare BBAR & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BBAR

Banco BBVA Argentina S.A. ADS

HOLD

Current Price

$13.60

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$22.70

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBAR
IMNM
Founded
1886
2006
Country
Argentina
United States
Employees
N/A
177
Industry
Commercial Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.7B
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
BBAR
IMNM
Price
$13.60
$22.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
10
Target Price
$17.00
$32.80
AVG Volume (30 Days)
481.8K
881.4K
Earning Date
05-20-2026
05-08-2026
Dividend Yield
2.04%
N/A
EPS Growth
N/A
51.40
EPS
N/A
N/A
Revenue
N/A
$6,941,000.00
Revenue This Year
$18.32
N/A
Revenue Next Year
$11.04
$1,127.34
P/E Ratio
$26.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.76
$7.15
52 Week High
$23.10
$27.65

Technical Indicators

Market Signals
Indicator
BBAR
IMNM
Relative Strength Index (RSI) 35.38 50.89
Support Level $13.13 $19.23
Resistance Level $17.10 $22.86
Average True Range (ATR) 0.74 0.96
MACD -0.27 -0.10
Stochastic Oscillator 5.22 23.54

Price Performance

Historical Comparison
BBAR
IMNM

About BBAR Banco BBVA Argentina S.A. ADS

Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: